Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RB1 | P06400 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28866348 | 0.81 | NR2E1 (0.58) | NR2E1TP53HPGDHSD17B10HTR2A | |
| SCHEMBL4497186 | 0.80 | VPS4B (0.51) | HTR2A | |
| SCHEMBL4288282 | 0.78 | NR2E1 (0.67) | NR2E1TP53HPGDHSD17B10HTR2A | |
| SCHEMBL700531 | 0.78 | NR2E1 (1.00) | NR2E1TP53HPGDHSD17B10HTR2A | |
| SCHEMBL29670383 | 0.78 | NR2E1 (1.00) | NR2E1TP53HPGDHSD17B10HTR2A | |
| SCHEMBL2515919 | 0.78 | NR2E1 (0.67) | NR2E1TP53HPGDHSD17B10HTR2A | |
| SCHEMBL833503 | 0.78 | NR2E1 (1.00) | NR2E1TP53HPGDHSD17B10HTR2A | |
| SCHEMBL21900686 | 0.78 | NR2E1 (0.67) | NR2E1TP53HPGDHSD17B10HTR2A | |
| SCHEMBL21754250 | 0.78 | NR2E1 (0.67) | NR2E1TP53HPGDHSD17B10HTR2A | |
| SCHEMBL834930 | 0.78 | NR2E1 (1.00) | NR2E1TP53HPGDHSD17B10HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396278-A | Carbazole derivatives as dopamine D3 receptor selectivity modulators | 北京大学 | 2023-07-07 | — | — | CN | disclosed |
| CN-104402798-B | A kind of 3-amino-1, the method for splitting of 2,3,4-tetrahydro carbazoles | 杭州瑞德化工有限公司 | 2016-09-14 | — | — | CN | disclosed |
| CN-105693595-A | Synthesis method for (R)-3-amino-1,2,3,4-tetrahydrocarbazole | 上海亚兴生物医药科技有限公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-105693595-A | Synthesis method for (R)-3-amino-1,2,3,4-tetrahydrocarbazole | 上海亚兴生物医药科技有限公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-104402798-A | Resolution method for 3-amino-1, 2, 3, 4-tetrahydrocarbazole | HANGZHOU READ CHEMICAL CO LTD | 2015-03-11 | — | — | CN | disclosed |
| US-20030203901-A1 | Methods of modulating tyrosine protein kinase function with indolinone compounds | SUGEN, INC. | 2003-10-30 | — | — | US | disclosed |
| US-6514981-B1 | By contacting cells expressing said protein tyrosine kinase with compound | SUGEN, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| CN-1015711-B | Cycloalkaho [1,2-b] indole-sulphonamides | BAYER AG (DE) | 1992-03-04 | — | — | CN | disclosed |
| CN-87100773-A | Cycloalkanes is [1,2-b] indoles-sulfamide compound also | — | 1987-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203901-A1 | Methods of modulating tyrosine protein kinase function with indolinone compounds | LCK, ABL1, PNCK | NR2E1 2152/4885TP53 974/4885HPGD 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.